Introduction
Cancer-associated thrombosis (CAT) is a serious complication and a leading cause of death second to cancer progression among patients with cancer [1‐3]. Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Whether or not the long-term mortality is increased in individuals surviving the initial VTE episode is less clear [4]. Risk of VTE is 4- to 7-fold higher in patients with cancer compared with the general population [5], with incidence rates (IRs) for all cancer types ranging from 2 to 12 cases per 100 person-years [6]. The risk of recurrent VTE (rVTE) events is also increased in individuals with anticoagulants and cancer-specific treatments [6].
Recommended treatments for CAT have changed recently, now including direct oral anticoagulants (DOACs; e.g. rivaroxaban, edoxaban, apixaban) and low molecular weight heparin (LMWH; e.g. dalteparin, enoxaparin, tinzaparin) as standard of care for CAT in patients with low risk of gastrointestinal or urogenital bleeding [7‐9]. Although meta-analyses have confirmed the role of LMWH in both the initial anticoagulation period and for long-term treatment, patients’ adherence was low in long-term treatment studies given the requirements for daily subcutaneous injection [10]. In contrast, the convenience of DOAC may improve adherence and patient outcomes [11]. Shared decision-making with patients is recommended, considering the potential lower risk of VTE recurrences associated with DOACs but higher bleeding risk as compared to LMWH [8, 9]. Rivaroxaban may be more effective in treating patients with CAT, significantly reducing recurrent thrombosis compared with LMWH, without increasing major bleeding and all-cause mortality, but there is heterogeneity among published studies [12‐18].
Anzeige
The present Observational Study of Cancer Associated Thrombosis for Rivaroxaban in SwEden (OSCAR-SE) aimed at examining the incidence of rVTE, major bleeding, and all-cause mortality in patients diagnosed with CAT treated with rivaroxaban compared with LMWH, based on data from national health registries in Sweden.
Methods
Ethical approval
An ethical application was submitted to the national ethical committee. Similarly, a scientific application was submitted to the national board of health and welfare asking for permission to obtain the necessary record linkages and release of data from named sources. All analyses were conducted on pseudo-anonymized individual data.
Study design
This cohort study was based on available nationwide health register data in Sweden. All individuals with a Swedish personal identification number and a diagnosis of cancer between 2013 and 2019 followed by a subsequent diagnosis of VTE within the next 6 months were identified and followed until the date of outcome, death, emigration, or end of follow-up on 31 December, 2020, whichever occurred first. The date of the first VTE after cancer diagnosis was the index event corresponding to start of follow-up.
Setting
All residents in Sweden diagnosed with cancer during the study period were identified through the Swedish Cancer Register (SCR) and linked to other national health and sociodemographic registers (National Patient Register [NPR], Prescribed Drug Register [PDR], Total Population Register [TPR], and Cause of Death Register [CDR]). Individuals were linked through their unique personal identifier given at birth or immigration.
Anzeige
Patients included fulfilled the inclusion criteria of having a non-autopsy cancer recorded in SCR 2013–2019 with a subsequent VTE diagnosis registered in NPR (inpatient or outpatient) in the following 183 days, living in Sweden at least 183 days before the index-VTE and being 18 years of age or older at the index-VTE. Moreover, they fulfilled none of the exclusion criteria of excluding diagnoses (atrial fibrillation, hip/knee replacement, or acute coronary syndrome) or treatment (DOAC, vitamin K antagonist, or LMWH), both within 183 days before the index-VTE, and had not a cancer type associated with increased bleeding risk according to the International Society on Thrombosis and Haemostasis (ISTH) guideline [9]. Excluded cancers were lip/upper gastrointestinal cancer, malignant immunoproliferative diseases, leukaemia and non-melanoma skin cancer (Supplementary Table S1).
Data sources
The data quality in SCR is high, with almost 99% of all cancer diagnoses morphologically verified, and with quality controlled at regional cancer centres before submission to the National Board of Health and Welfare [19]. The NPR, used for outcomes and comorbidities, includes information about diagnoses and surgical procedures from hospitals and visits to specialist care. Diagnoses are coded according to the current 10th version of International Classification of Diseases (ICD-10). The validity of NPR is high, with positive predictive values generally around 85–95% for most diagnoses [20]. The PDR provides information on all dispensed prescriptions from pharmacies with substances coded according to the Anatomic Therapeutic Chemical Classification System, date of purchase, and amount dispensed in defined daily doses [21]. The TPR holds information about, among others, education, employment status, income, marital status, region of residency, and migration [22]. The CDR provides information about causes and dates of death [23].
Outcomes variables
The outcome rVTE was defined as a diagnosis of DVT or PE recorded as main diagnosis at discharge from hospital. Major bleeding was defined as a diagnosis of intracranial, gastrointestinal, urogenital, or other bleeding recorded as a main diagnosis at discharge from hospital. All-cause mortality was retrieved from CDR. For codes defining outcomes, see Supplementary Table S1.
Statistical methods
Exposure was defined as the first dispensation of rivaroxaban or LMWH within 28 days after the index VTE. The main exposure measure was the intention-to-treat (ITT) approach, i.e., each individual was assigned to their first recorded treatment after their index-VTE and was assumed to stay on that until censoring. As a sensitivity analysis, the on-treatment exposure measure was applied, where each individual’s exposure stopped at estimated end of supply, or switch. Exposure duration was estimated according to consecutive dispensed prescriptions and amount of dispensed medication.
IRs with 95% Poisson confidence intervals (CIs) were calculated overall and for 3, 6, 12, and 24 months after index CAT.
The comparisons of the independent outcomes rVTE, major bleeding, and all-cause mortality used propensity score (PS) overlap weights [24]. Overlap weighting assigns weights to each patient that are proportional to the probability of belonging to the opposite treatment group. The PS model included 85 variables identified as potential confounders, including demographics, comorbidities, medications, and cancer characteristics, see Supplementary Table S2.
Cox proportional hazards regression were applied to compare time to event for the outcomes between treatment groups using the robust variance sandwich estimator [25]. The only independent variable included in the Cox models was anticoagulant received (rivaroxaban or LMWH), since the PS overlap weights balance the characteristics included in the PS. Standardized differences before/after adjusting by PS overlap weights were explored using Love plots. Hazard ratios (HRs) are presented with 95% CIs.
As a sensitivity analysis, death was considered a competing risk for the outcomes rVTE and major bleeding. Fine–Gray regression subhazards [26] were estimated using PS overlap weighting. As an additional sensitivity analysis, we compared all DOACs (rivaroxaban, dabigatran, apixaban, edoxaban) to LMWH (Supplementary Table S5).
Anzeige
Results
A total of 5,464 individuals with CAT were included, of whom 283 used rivaroxaban and 5,181 used LMWH (Fig. 1). The proportion of included patients varied over study years, with more rivaroxaban-treated patients included later in the study period, whereas the inclusion of LMWH users was relatively constant over time. The majority of index-VTEs were PE, 55% for LMWH and 60% for rivaroxaban. Baseline characteristics are shown in Table 1. After applying PS overlap weighting, all included baseline characteristics were well balanced (see Table 1, Supplementary Table S2, and Supplementary Fig. S1).
Table 1
Selected baseline characteristics after exclusion on treatment, including ISTH cancers only, with treatment within 28 days after index-VTE; frequency (proportion) for rivaroxaban and LMWH, before and after PS overlap weighting
Before PS overlap weighting | After PS overlap weighting | ||||
|---|---|---|---|---|---|
Variable | Value | Rivaroxaban | LMWH | Rivaroxaban | LMWH |
Total number | 283 | 5181 | 200 | 200 | |
Age | <65 | 78 (28%) | 1739 (34%) | 57 (28%) | 57 (28%) |
>=65 | 205 (72%) | 3442 (66%) | 143 (72%) | 143 (72%) | |
Sex | Female | 137 (48%) | 2952 (57%) | 103 (51%) | 103 (51%) |
Male | 146 (52%) | 2229 (43%) | 97 (49%) | 97 (49%) | |
Inclusion year | 2013 | 12 (4%) | 766 (15%) | 7 (3%) | 7 (3%) |
2014 | 40 (14%) | 744 (14%) | 22 (11%) | 22 (11%) | |
2015 | 49 (17%) | 746 (14%) | 36 (18%) | 36 (18%) | |
2016 | 37 (13%) | 753 (15%) | 32 (16%) | 32 (16%) | |
2017 | 56 (20%) | 746 (14%) | 33 (17%) | 33 (17%) | |
2018 | 50 (18%) | 769 (15%) | 36 (18%) | 36 (18%) | |
2019 | 39 (14%) | 657 (13%) | 34 (17%) | 34 (17%) | |
Type of VTE | DVT | 102 (36%) | 2122 (41%) | 73 (36%) | 73 (36%) |
PE | 171 (60%) | 2828 (55%) | 120 (60%) | 120 (60%) | |
Both | 10 (4%) | 231 (4%) | 7 (3%) | 7 (3%) | |
Cancer type | Oral cavity and pharynx | 2 (0.7%) | 67 (1%) | 2 (1%) | 2 (1%) |
Digestive organs | 52 (18%) | 1561 (30%) | 42 (21%) | 42 (21%) | |
Respiratory and intrathoracic organs | 14 (5%) | 946 (18%) | 12 (6%) | 12 (6%) | |
Bone and articular cartilage | 0 (0.00%) | 11 (0.2%) | 0 (0.00%) | 0 (0.00%) | |
Malignant melanoma | 37 (13%) | 51 (1%) | 15 (8%) | 15 (8%) | |
Mesothelial and soft tissue | 2 (0.7%) | 57 (1%) | 2 (0.9%) | 2 (0.9%) | |
Breast | 30 (11%) | 606 (12%) | 24 (12%) | 24 (12%) | |
Female genital organs | 14 (5%) | 382 (7%) | 12 (6%) | 12 (6%) | |
Male genital organs | 58 (20%) | 265 (5%) | 33 (17%) | 33 (17%) | |
Urinary tract | 17 (6%) | 321 (6%) | 14 (7%) | 14 (7%) | |
Eye, brain, and other parts of central nervous system | 27 (10%) | 350 (7%) | 22 (11%) | 22 (11%) | |
Thyroid and other endocrine glands | 11 (4%) | 30 (0.6%) | 6 (3%) | 6 (3%) | |
Ill-defined, secondary, and unspecified | 1 (0.4%) | 188 (4%) | 1 (0.5%) | 1 (0.5%) | |
Lymphoid, haematopoietic and related tissue | 18 (6%) | 346 (7%) | 15 (7%) | 15 (7%) | |
Aggregated TNM | 0 | 30 (11%) | 159 (3%) | 17 (9%) | 17 (9%) |
1 | 70 (25%) | 718 (14%) | 44 (22%) | 44 (22%) | |
2 | 58 (20%) | 820 (16%) | 38 (19%) | 38 (19%) | |
3 | 26 (9%) | 1080 (21%) | 22 (11%) | 22 (11%) | |
4 | 20 (7%) | 914 (18%) | 17 (9%) | 17 (9%) | |
Missing | 79 (28%) | 1490 (29%) | 62 (31%) | 62 (31%) | |
Hospital duration during 1 year before index date | 0 weeks | 158 (56%) | 2443 (47%) | 103 (52%) | 103 (52%) |
1–2 weeks | 84 (30%) | 1779 (34%) | 65 (33%) | 65 (33%) | |
3–10 weeks | 38 (13%) | 904 (17%) | 31 (16%) | 31 (16%) | |
>10 weeks | 3 (1%) | 55 (1%) | 0 (0.2%) | 0 (0.2%) | |
Education | Elementary school | 97 (34%) | 1484 (29%) | 71 (36%) | 71 (36%) |
High school | 114 (40%) | 2307 (45%) | 80 (40%) | 80 (40%) | |
College/university | 63 (22%) | 1282 (25%) | 43 (22%) | 43 (22%) | |
Postgraduate | 8 (3%) | 55 (1%) | 6 (3%) | 6 (3%) | |
Missing | 1 (0.4%) | 53 (1%) | 0 (0.00%) | 0 (0.00%) | |
Employment | Employed | 87 (31%) | 1745 (34%) | 64 (32%) | 64 (32%) |
Not employed | 196 (69%) | 3432 (66%) | 136 (68%) | 136 (68%) | |
Missing | 0 (0.00%) | 4 (0.08%) | 0 (0.00%) | 0 (0.00%) | |
Income quintiles | Low | 61 (22%) | 1109 (21%) | 44 (22%) | 44 (22%) |
Low–mid | 58 (20%) | 1055 (20%) | 43 (21%) | 43 (21%) | |
Mid | 59 (21%) | 1080 (21%) | 40 (20%) | 40 (20%) | |
Mid–high | 52 (18%) | 985 (19%) | 38 (19%) | 38 (19%) | |
High | 53 (19%) | 948 (18%) | 36 (18%) | 36 (18%) | |
Missing | 0 (0.00%) | 4 (0.08%) | 0 (0.00%) | 0 (0.00%) | |
Marital status | Married | 145 (51%) | 2754 (53%) | 100 (50%) | 100 (50%) |
Divorced | 43 (15%) | 914 (18%) | 31 (16%) | 31 (16%) | |
Unmarried | 45 (16%) | 867 (17%) | 34 (17%) | 34 (17%) | |
Widowed | 50 (18%) | 642 (12%) | 35 (17%) | 35 (17%) | |
Missing | 0 (0.00%) | 4 (0.08%) | 0 (0.00%) | 0 (0.00%) | |
Region | Predominantly urban (Stockholm) | 12 (4%) | 1002 (19%) | 11 (5%) | 11 (5%) |
Intermediate (Malmö, Gothenburg) | 122 (43%) | 1544 (30%) | 84 (42%) | 84 (42%) | |
Predominantly rural (all other) | 149 (53%) | 2631 (51%) | 104 (52%) | 104 (52%) | |
Missing | 0 (0.00%) | 4 (0.08%) | 0 (0.00%) | 0 (0.00%) | |
Table 2 includes IRs, weighted and unweighted HRs and sub-HRs for rVTE, major bleeding, and all-cause mortality, comparing rivaroxaban with LMWH under ITT exposure. Kaplan–Meier graphs for all outcomes by treatment are presented in Fig. 2. Comparison of all DOACs with LMWH under ITT exposure showed similar results as presented in Supplementary Table S5.
Fig. 1
Inclusion flowchart from source population of individuals with cancer induced thrombosis to study population of individuals treated with rivaroxaban or LMWH
×
![]()
Anzeige
Fig. 2
Kaplan–Meier graphs for all outcomes by treatment. Panel (a) = Recurrent VTE, panel (b) = Major bleeding, and panel (c) = All-cause mortality. LMWH, low molecular weight heparin; VTE, venous thromboembolism. Graph created using STATA, StataCorp. 2020. Stata Statistical Software: Version 17.0. College Station, TX: StataCorp LLC
×
![]()
Table 2
Incidence rates, unweighted and weighted hazard ratios from Cox regression and unweighted and weighted subhazards from Fine–Gray regression for recurrent VTE and major bleeding; rivaroxaban vs. LMWH under ITT exposure definition
Outcome | Months follow-up | Group | Events (N) | Person-years | IR (CI) per 1000 PY | Unweighted HR (CI)* | Weighted HR (CI) | Unweighted sub-HR (CI)a | Weighted sub-HR (CI) |
|---|---|---|---|---|---|---|---|---|---|
Recurrent VTE | 0–3 | RVX | 12 | 66 | 181.1 (93.55–316.3) | 0.91 (0.51–1.63) | 0.80 (0.40–1.60) | 0.94 (0.52–1.68) | 0.81 (0.33–2.02) |
LMWH | 230 | 1121 | 205.2 (179.5–233.5) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
0–6 | RVX | 13 | 129 | 100.5 (53.53–171.9) | 0.84 (0.48–1.46) | 0.75 (0.38–1.45) | 0.89 (0.51–1.56) | 0.77 (0.32–1.83) | |
LMWH | 262 | 2043 | 128.3 (113.2–144.8) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
0–12 | RVX | 17 | 248 | 68.66 (40.00–109.9) | 0.81 (0.50–1.32) | 0.77 (0.43–1.35) | 0.93 (0.57–1.51) | 0.81 (0.38–1.74) | |
LMWH | 328 | 3583 | 91.55 (81.91–102.0) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
0–24 | RVX | 21 | 447 | 47.00 (29.09–71.84) | 0.78 (0.50–1.21) | 0.73 (0.44–1.23) | 0.96 (0.62–1.48) | 0.80 (0.40–1.61) | |
LMWH | 393 | 5896 | 66.66 (60.23–73.59) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
Overall | RVX | 25 | 850 | 29.41 (19.03–43.41) | 0.73 (0.49–1.10) | 0.70 (0.44–1.13) | 0.98 (0.65–1.46) | 0.80 (0.42–1.53) | |
LMWH | 473 | 10,524 | 44.95 (40.99–49.19) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
Major bleeding | 0–3 | RVX | 2 | 68 | 29.39 (3.56–106.2) | 0.35 (0.09–1.40) | 0.40 (0.09–1.74) | 0.37 (0.09–1.51) | 0.41 (0.06–2.92) |
LMWH | 93 | 1150 | 80.87 (65.27–99.07) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
0–6 | RVX | 3 | 133 | 22.55 (4.65–65.90) | 0.32 (0.10–0.99) | 0.42 (0.12–1.38) | 0.36 (0.12–1.14) | 0.44 (0.09–2.16) | |
LMWH | 141 | 2096 | 67.26 (56.62–79.32) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
0–12 | RVX | 6 | 256 | 23.46 (8.61–51.06) | 0.48 (0.21–1.08) | 0.62 (0.26–1.49) | 0.59 (0.26–1.32) | 0.68 (0.20–2.33) | |
LMWH | 181 | 3682 | 49.16 (42.26–56.86) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
0–24 | RVX | 10 | 460 | 21.73 (10.42–39.97) | 0.62 (0.33–1.17) | 0.71 (0.35–1.46) | 0.81 (0.43–1.52) | 0.81 (0.28–2.32) | |
LMWH | 218 | 6063 | 35.96 (31.34–41.06) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
Overall | RVX | 17 | 872 | 19.51 (11.36–31.23) | 0.80 (0.50–1.30) | 1.04 (0.60–1.82) | 1.13 (0.70–1.84) | 1.27 (0.53–3.02) | |
LMWH | 273 | 10,918 | 25.00 (22.13–28.15) | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
All-cause mortality | 0–3 | RVX | 13 | 68 | 190.4 (101.4–325.6) | 0.21 (0.12–0.36) | 0.47 (0.27–0.83) | Competing risk | |
LMWH | 955 | 1161 | 822.7 (771.3–876.5) | 1 (Ref) | 1 (Ref) | ||||
0–6 | RVX | 21 | 134 | 156.7 (97.01–239.6) | 0.20 (0.13–0.31) | 0.41 (0.26–0.65) | |||
LMWH | 1522 | 2127 | 715.4 (679.9–752.3) | 1 (Ref) | 1 (Ref) | ||||
0–12 | RVX | 38 | 259 | 146.8 (103.9–201.5) | 0.24 (0.18–0.33) | 0.48 (0.34–0.67) | |||
LMWH | 2125 | 3757 | 565.6 (541.8–590.2) | 1 (Ref) | 1 (Ref) | ||||
0–24 | RVX | 54 | 468 | 115.3 (86.59–150.4) | 0.26 (0.20–0.34) | 0.48 (0.36–0.64) | |||
LMWH | 2628 | 6220 | 422.5 (406.5–439.0) | 1 (Ref) | 1 (Ref) | ||||
Overall | RVX | 70 | 896 | 78.11 (60.89–98.68) | 0.28 (0.22–0.35) | 0.50 (0.39–0.64) | |||
LMWH | 3084 | 11,309 | 272.7 (263.2–282.5) | 1 (Ref) | 1 (Ref) | ||||
For rVTE comparing rivaroxaban with LMWH, the weighted HR was similar for different follow-up times and no results were statistically significant. For rivaroxaban, 12 out of 25 cases of rVTE happened during the 3-month follow-up, compared with 230 out of 473 for LMWH. When considering death as a competing risk, the sub-HRs were similar to the corresponding HRs, but with broader CIs. Both HR and sub-HR of major bleeding favoured rivaroxaban, and no results were statistically significant. For the comparison of mortality between rivaroxaban and LMWH all results were statistically significant, favouring rivaroxaban with point estimates close to 0.5, which did not change much for different follow-up times.
The on-treatment analysis showed consistent results for the three outcomes, as shown in Supplementary Table S4.
Anzeige
Discussion
The risk of rVTE appears to be similar in patients treated with rivaroxaban compared with LMWH. The results for major bleeding appeared similar to those of rVTE. Sub-HRs considering death as competing events were similar to the HRs from Cox regression. A consistently lower all-cause mortality for rivaroxaban compared with LMWH was observed for all follow-up times.
In observational studies, there are discrepancies in the HRs comparing rivaroxaban with LMWH regarding rVTE, major bleeding, and mortality. Costa et al. used the US Surveillance, Epidemiology, and End Results–Medicare-linked data, including patients with CAT who were admitted to hospital or treated in an emergency department and subsequently prescribed rivaroxaban or LMWH for outpatient anticoagulation. Costa et al. applied a PS-matched approach. No differences were observed for major bleeding with a HR 1.01 (95% CI 0.50–2.01) and a mortality HR 0.87 (95% CI 0.70–1.07), but rivaroxaban reduced rVTE with a HR 0.37 (95% CI 0.15–0.95) [27]. An observational study by Coleman et al., showed a HR for rVTE of 0.69 (95% CI 0.51–0.92), without differences in major bleeding (HR 0.79 [95% CI 0.55–1.13]) and all-cause mortality (HR 1.07 [95% CI 0.85–1.35]) for rivaroxaban compared to LMWH [18]. In agreement, another observational study by Streiff et al. included 707 patients with CAT treated with rivaroxaban and 660 patients treated with LMWH for 3 months using data from claims, showing that rVTE was significantly lower for rivaroxaban with a HR 0.72 (95% CI 0.52–0.95), and with similar rates of major bleeding [15].
A retrospective cohort study of 4000 individuals with CAT comparing DOACs with LMWH by Riaz et al., additionally reported a higher risk of rVTE, higher risk of major bleeding, and also an increased risk of all-cause mortality (HR, 1.61; 95% CI, 1.15–2.25) with LMWH [28]. A meta-analysis of real-world data and randomized controlled trials (RCTs) comparing rivaroxaban with LMWH in patients with CAT by Mohamed et al., showed fewer rVTE events, lower all-cause mortality, similar major bleeding risk, and a higher risk of clinically relevant non-major bleeding events for rivaroxaban [16]. Another meta-analysis by Song et al., found similar results considering rVTE and bleeding after 12 months of follow-up [17]. For comparison, the weighted adjusted HRs in the current study were 0.91 for rVTE and 0.65 for major bleeding, both closer to 1 and not statistically significant, and with a HR of 0.57 for all-cause mortality being significant. The reported differences among studies may be related to the design, the included population, the definition of exposure, and/or differences in outcomes between RCTs and observational studies.
In the current study, upper gastrointestinal malignancies were excluded due to higher bleeding risk. Given that individual decisions on anticoagulation treatment are done considering bleeding and thrombosis risk for each patient, this potential restriction to external validity excluding patients with higher risk of bleeding may be consistent with clinical practice in a real-world setting. Different cancer subpopulations also showed some discrepancies. Rivaroxaban compared with LMWH had similar rVTE risk, but higher risk of bleeding in patients with CAT and active locally advanced unresectable or metastatic cancers, especially upper gastrointestinal tract and hepatopancreatobiliary cancers [29]. These findings were also supported by a meta-analysis of gastrointestinal cancers [30]. No difference was observed in rVTE, major bleeding, or all-cause mortality in long-term treatment with rivaroxaban compared with dalteparin in patients with CAT associated with lung [31] or gynaecologic cancer [32].
The lower all-cause mortality with rivaroxaban compared with LMWH in the current study is consistent with some published observational studies [13, 14], but inconsistent with results from RCTs [12, 33, 34].This discrepancy suggests that despite adjusting for confounders, there are unmeasured confounders such as systemic treatment for cancer, severity of cancer and other comorbidities, lifestyle factors, family history of VTE, indications for prescriptions and physicians’ choice of treatment. Hence, interpretation of results, specifically regarding mortality, should be made with caution.
Effectiveness and safety outcomes in the current study are supportive of current treatment guidelines for VTE in patients with cancer that recommend the use of DOACs or LMWH for initial treatment within the first week and for short-term treatment (3 to 6 months) [8, 9]. For longer-term treatment, persistence is likely to be higher with DOACs than LMWH due to easier administration and proven higher treatment adherence [11, 35], but there is a paucity of evidence comparing the efficacy and safety of DOACs beyond that first 6–12 months of therapy with LMWH. Treatment decisions should balance benefits and harms, integrating individual values, preferences, and available alternative strategies [11].
Strengths of the current study include long-term follow-up with no loss to follow-up, with relatively large sample size. We included all CAT cases in Sweden, without any selection, allowing estimation of an overall risk of rVTE and bleeding in patients with cancers not associated with high bleeding risk consistent with the ISTH’s recommendation. CAT populations have increased mortality, and hence death was handled as a competing event for rVTE and bleeding in additional analyses.
Some limitations include the following: first, exposure to drugs provided during hospitalizations were not captured in this study, unless they were dispensed to the patient through their personal identifier. Second, the relatively small sample size, particularly in the rivaroxaban group, influenced the precision of the HRs and the sub-HRs resulting in broad CIs making small effect sizes hard to interpret. Third, it is possible that residual confounding from unmeasured confounders, for example, comorbidities and cancer prognosis, are the main driver in the observed difference in mortality between the exposure groups. Fourth, channelling bias may still have an effect on the results [36]. As an example, if physicians preferentially prescribe LMWH over DOACs to patients with a high bleeding risk, the resulting relative risk estimate comparing DOACs with LMWH could be biased in direction towards the null. Despite this, the comparison groups were balanced by PS overlap weighting, including all available identified confounders. Fifth, the time period covered by this study may not reflect current cancer therapies or how DOACs are currently used, since the pivotal RCTs comparing DOACs with LMWH were published late (mid-2018) in the study period. Therefore, it is possible that rivaroxaban was used in selected cancer patients.
Conclusion
In patients with CAT who do not have a cancer with a high risk of bleeding, treatment with rivaroxaban appears to perform similarly to LMWH for rVTE and major bleeding at 3, 6, 12, and 24 months of follow-up. Rivaroxaban was associated with a lower risk of death as compared with LMWH. However, results for mortality should be interpreted with caution since this observation may be a result of residual confounding.
Declarations
Ethics approval and consent to participate
ML, DHG, and AE report participation in research projects funded by Bayer AG and other pharmaceutical companies, all regulator-mandated phase IV-studies, all with funds paid to the institution where they were employed (no personal fees). CB reports consulting fees and honoraria from Bayer AG, consulting fees and honoraria from Bristol Myers Squibb, consulting fees and honoraria from Daiichi Sankyo, and consulting fees from Pfizer. KV, YB, GP, KA, MR, and BS are employees of Bayer AG, or were employees at the time of data generation/manuscript preparation. MC reports grants and consulting fees from Pfizer, grants and consulting fees from LEO Pharma, grants and consulting fees from Bristol Myers Squibb, consulting fees from Bayer AG, consulting fees from Sanofi, and consulting fees from Servier. ATC reports grants, consulting fees and honoraria from Alexion/AstraZeneca, grants, consulting fees and honoraria from Bristol Myers Squibb/Pfizer, and consulting fees and honoraria from Bayer AG. CIC reports grants, consulting fees and travel support from Bayer AG, grants and consulting fees from Janssen Pharmaceuticals, grants and consulting fees from Alexion Pharmaceutical, and honoraria from Medscape. AAKa reports consulting fees, honoraria and travel support from Bayer AG, consulting fees, honoraria and travel support from Janssen, consulting fees and honoraria from Bristol Myers Squibb, consulting fees and honoraria from Anthos, consulting fees and honoraria from Pfizer, consulting fees and honoraria from Sanofi, and honoraria from WebMD. AYYL reports consulting fees and honoraria from Bayer AG, consulting fees and honoraria from LEO Pharma, consulting fees and honoraria from Pfizer, consulting fees from Servier and honoraria from Bristol Myers Squibb. GB is a consultant to Bayer AG.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.